• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.PROSTVAC用于转移性去势抵抗性前列腺癌男性患者的II期随机双盲对照研究的修订总生存分析
J Clin Oncol. 2017 Jan;35(1):124-125. doi: 10.1200/JCO.2016.69.7748. Epub 2016 Sep 30.
2
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.无症状或轻度症状转移性去势抵抗性前列腺癌的 PROSTVAC III 期临床试验。
J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
3
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.去势抵抗性前列腺癌的治疗性疫苗与免疫疗法：当前进展及临床应用
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166.
4
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
5
Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.转移性去势抵抗性前列腺癌的免疫治疗：优化的过去和未来策略。
Curr Urol Rep. 2019 Sep 3;20(10):64. doi: 10.1007/s11934-019-0931-3.
6
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.间歇性化疗作为转移性去势抵抗性前列腺癌患者新型药物测试平台：美国国防部前列腺癌临床试验联盟多西他赛联合泼尼松间歇性给药联合或不联合维持性粒细胞巨噬细胞集落刺激因子的随机II期试验
Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9.
7
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.粒细胞-巨噬细胞集落刺激因子转导的同种异体前列腺癌细胞联合 ipilimumab 治疗转移性去势抵抗性前列腺癌患者：一项 1 期剂量递增试验。
Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.
8
PROSTVAC® targeted immunotherapy candidate for prostate cancer.用于前列腺癌的PROSTVAC®靶向免疫疗法候选药物。
Immunotherapy. 2014;6(3):235-47. doi: 10.2217/imt.13.176.
9
Immunotherapeutics in development for prostate cancer.正在研发的用于前列腺癌的免疫疗法。
Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2.
10
[Current status and prospects of immunotherapy for castration-resistant prostate cancer].[去势抵抗性前列腺癌免疫治疗的现状与前景]
Nihon Rinsho. 2014 Dec;72(12):2174-8.

引用本文的文献

1
Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook.前列腺癌的疫苗疗法：现状与未来展望
Vaccines (Basel). 2024 Dec 9;12(12):1384. doi: 10.3390/vaccines12121384.
2
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR.前列腺癌管理的最新策略综合述评：治疗靶点和 SAR。
Mini Rev Med Chem. 2024;24(7):721-747. doi: 10.2174/1389557523666230911141339.
3
The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy.溶瘤病毒在癌症免疫治疗中的临床进展
Cureus. 2023 Jun 21;15(6):e40742. doi: 10.7759/cureus.40742. eCollection 2023 Jun.
4
Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.前列腺癌的免疫治疗：现状与新的治疗前景。
Curr Oncol. 2023 Jun 13;30(6):5769-5794. doi: 10.3390/curroncol30060432.
5
Tumor microenvironment signaling and therapeutics in cancer progression.肿瘤微环境信号与癌症进展中的治疗策略。
Cancer Commun (Lond). 2023 May;43(5):525-561. doi: 10.1002/cac2.12416. Epub 2023 Apr 2.
6
Progression in immunotherapy for advanced prostate cancer.晚期前列腺癌免疫治疗的进展。
Front Oncol. 2023 Feb 28;13:1126752. doi: 10.3389/fonc.2023.1126752. eCollection 2023.
7
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.癌症疫苗的最新进展：挑战、成就与未来前景
Vaccines (Basel). 2022 Nov 25;10(12):2011. doi: 10.3390/vaccines10122011.
8
Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.前列腺癌免疫疗法：新型治疗方法及疗效的近期进展综述
Am J Clin Exp Urol. 2022 Aug 15;10(4):210-233. eCollection 2022.
9
Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease.开发去势抵抗性前列腺癌和复发性疾病的新治疗方案。
Biomedicines. 2022 Aug 3;10(8):1872. doi: 10.3390/biomedicines10081872.
10
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.基于疫苗的免疫治疗方案（VBIR）的临床前开发，该方案可诱导针对肿瘤相关自身抗原的有效和持久的 T 细胞反应。
Cancer Immunol Immunother. 2023 Feb;72(2):287-300. doi: 10.1007/s00262-022-03245-x. Epub 2022 Jul 13.

本文引用的文献

1
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

作者信息

Kantoff Philip W, Gulley James L, Pico-Navarro Cesar

机构信息

Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

出版信息

J Clin Oncol. 2017 Jan;35(1):124-125. doi: 10.1200/JCO.2016.69.7748. Epub 2016 Sep 30.

DOI:10.1200/JCO.2016.69.7748
PMID:27646950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6411419/
Abstract
摘要